A phase III study of PSC-833 [valspodar] in combination with vincristine, doxorubicin, and dexamethasone (PSC 833/VAD) versus VAD alone in patients with relapsing or refractory multiple myeloma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Dexamethasone; Doxorubicin; Valspodar; Vincristine
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 29 Aug 2013 Biomarkers information updated
- 10 Sep 2005 New trial record.